Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Sweden
  4. Nasdaq Stockholm
  5. Saniona AB (publ)
  6. Summary
    SANION   SE0005794617

SANIONA AB (PUBL)

(SANION)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensus 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq Stockholm
11/29/2021 11/30/2021 12/01/2021 12/02/2021 12/03/2021 Date
10.02(c) 10.6(c) 9.71(c) 10.1(c) 10.3(c) Last
62 468 240 057 130 694 148 328 179 532 Volume
-0.20% +5.79% -8.40% +4.02% +1.98% Change
More quotes
Estimated financial data (e)
Sales 2019 7,20 M 0,79 M 0,79 M
Net income 2019 -68,8 M -7,52 M -7,52 M
Net cash position 2019 38,2 M 4,18 M 4,18 M
P/E ratio 2019 -9,61x
Yield 2019 -
Sales 2020 8,20 M 0,90 M 0,90 M
Net income 2020 -73,4 M -8,03 M -8,03 M
Net cash position 2020 526 M 57,6 M 57,6 M
P/E ratio 2020 -11,5x
Yield 2020 -
Capitalization 643 M 70,2 M 70,3 M
EV / Sales 2019 96,1x
EV / Sales 2020 92,5x
Nbr of Employees 52
Free-Float 87,1%
More Financials
Company
Saniona AB is a Sweden-based company active in the field of biotechnology. It operates in the area of drugs targeting ion channels to develop therapeutics for pain, central nervous system, and inflammatory or autoimmune diseases. The Company develops a technology platform which enables investigation of all types of ion channel drug targets. Its research is focused on GABAA receptors, nicotinic acetylcholine... 
More about the company
All news about SANIONA AB (PUBL)
12/02Saniona Chairman J. Donald deBethizy and CEO Rami Levin, as well as additional members ..
AQ
11/26Saniona AB's Nomination Committee for the Annual General Meeting 2022
AQ
11/25Saniona AB's Nomination Committee for the Annual General Meeting 2022
AQ
11/22BIOSTOCK : áSaniona initiates clinical trial in rare disease
AQ
11/18Saniona publishes its interim report for the third quarter of 2021
AQ
11/18Saniona AB Reports Earnings Results for the Third Quarter and Nine Months Ended Septemb..
CI
11/17Saniona Initiates Phase 2b Clinical Trial of Tesomet for Hypothalamic Obesity
AQ
11/17Saniona Initiates Phase 2B Clinical Trial of Tesomet for Hypothalamic Obesity
CI
11/11BIOSTOCK : áSaniona's founder on 10 years of history and the future
AQ
11/11BIOSTOCK STUDIO : Saniona celebrates a decade of progress
AQ
10/19BIOSTOCK : áSaniona one step closer to clinical studies in HO and PWS
AQ
10/18SANIONA : completes submission of manufacturing data for Tesomet capsules to U.S. FDA
AQ
10/18Saniona Completes Submission of Manufacturing Data for Tesomet Capsules to U.S. FDA
CI
10/06SANIONA : to participate in multiple upcoming virtual investor conferences
AQ
09/27BIOSTOCK : áSaniona strengthens its board of directors
AQ
More news
News in other languages on SANIONA AB (PUBL)

- No features available -

More news
Chart SANIONA AB (PUBL)
Duration : Period :
Saniona AB (publ) Technical Analysis Chart | SANION | SE0005794617 | MarketScreener
Technical analysis trends SANIONA AB (PUBL)
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 1
Last Close Price 10,30 
Average target price
Spread / Average Target -
Managers and Directors
Rami Levin President & Chief Executive Officer
Jason A. Amello Chief Financial Officer
Joseph Donald DeBethizy Chairman
Palle Christophersen Chief Scientific Officer
Rudolf A. Baumgartner Chief Medical Officer & Head-Clinical Development
Sector and Competitors
1st jan.Capi. (M$)
SANIONA AB (PUBL)-50.97%70
GILEAD SCIENCES, INC.19.40%87 255
BIONTECH SE310.30%83 098
REGENERON PHARMACEUTICALS31.23%66 409
WUXI APPTEC CO., LTD.26.31%65 758
VERTEX PHARMACEUTICALS-13.76%51 819